Month: August 2023

Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023

“We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics…

Perspective Therapeutics to Present Clinical and Preclinical Data at the 36th Annual Congress of the European Association of Nuclear Medicine

Our team at Perspective Therapeutics continues to work diligently to advance much needed targeted alpha therapy using 212Pb,” said Thijs Spoor…

Cesium-131 in Cancer Care: Unpacking Its Role and Benefits

In the realm of medical treatments, especially those related to cancer, patients often come across various terminologies that might seem complex…

Unlocking the Potential of Cesium-131: Understanding Radiation Seed Therapy in Modern Cancer Treatment

Radiation therapy has been an integral part of cancer treatment for many years. One specific method that’s been gaining attention is the use of radiation brachytherapy seeds…

Perspective Therapeutics Reports Second Quarter Fiscal 2023 Results and Recent Business Highlights

• Phase I/2a clinical trials initiated: VMT-𝛼-NET for neuroendocrine tumors, and VMT01 for melanoma…

Perspective Therapeutics and GT Medical Technologies Collaborate to Expand Access to Unique Cesium-131 Based Brain Cancer Treatment

“We are delighted to announce the expansion of our collaboration with GT MedTech to increase our manufacturing in support of their objective of bringing GammaTile Therapy to more patients…

Scroll to top